87 related articles for article (PubMed ID: 23219600)
1. Peripheral site and acyl pocket define selective inhibition of mouse butyrylcholinesterase by two biscarbamates.
Bosak A; Smilović IG; Stimac A; Vinković V; Sinko G; Kovarik Z
Arch Biochem Biophys; 2013 Jan; 529(2):140-5. PubMed ID: 23219600
[TBL] [Abstract][Full Text] [Related]
2. Amino acid residues involved in stereoselective inhibition of cholinesterases with bambuterol.
Bosak A; Gazić I; Vinković V; Kovarik Z
Arch Biochem Biophys; 2008 Mar; 471(1):72-6. PubMed ID: 18167304
[TBL] [Abstract][Full Text] [Related]
3. Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
Bosak A; Gazić Smilović I; Sinko G; Vinković V; Kovarik Z
J Med Chem; 2012 Aug; 55(15):6716-23. PubMed ID: 22817559
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers.
Bosak A; Gazić I; Vinković V; Kovarik Z
Chem Biol Interact; 2008 Sep; 175(1-3):192-5. PubMed ID: 18582854
[TBL] [Abstract][Full Text] [Related]
5. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline.
Kovarik Z; Radić Z; Grgas B; Skrinjarić-Spoljar M; Reiner E; Simeon-Rudolf V
Biochim Biophys Acta; 1999 Aug; 1433(1-2):261-71. PubMed ID: 10446376
[TBL] [Abstract][Full Text] [Related]
6. Mutant cholinesterases possessing enhanced capacity for reactivation of their phosphonylated conjugates.
Kovarik Z; Radić Z; Berman HA; Simeon-Rudolf V; Reiner E; Taylor P
Biochemistry; 2004 Mar; 43(11):3222-9. PubMed ID: 15023072
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
[TBL] [Abstract][Full Text] [Related]
8. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
[TBL] [Abstract][Full Text] [Related]
9. Acetylcholinesterase active centre and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates.
Kovarik Z; Radić Z; Berman HA; Simeon-Rudolf V; Reiner E; Taylor P
Biochem J; 2003 Jul; 373(Pt 1):33-40. PubMed ID: 12665427
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers.
Sinko G; Kovarik Z; Reiner E; Simeon-Rudolf V; Stojan J
Biochimie; 2011 Oct; 93(10):1797-807. PubMed ID: 21740955
[TBL] [Abstract][Full Text] [Related]
11. Reversible inhibition of acetylcholinesterase and butyrylcholinesterase by 4,4'-bipyridine and by a coumarin derivative.
Simeon-Rudolf V; Kovarik Z; Radić Z; Reiner E
Chem Biol Interact; 1999 May; 119-120():119-28. PubMed ID: 10421445
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity.
Amitai G; Adani R; Yacov G; Yishay S; Teitlboim S; Tveria L; Limanovich O; Kushnir M; Meshulam H
Toxicology; 2007 Apr; 233(1-3):187-98. PubMed ID: 17129656
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon.
Amitai G; Moorad D; Adani R; Doctor BP
Biochem Pharmacol; 1998 Aug; 56(3):293-9. PubMed ID: 9744565
[TBL] [Abstract][Full Text] [Related]
14. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
15. Active site mutant acetylcholinesterase interactions with 2-PAM, HI-6, and DDVP.
Kovarik Z; Ciban N; Radić Z; Simeon-Rudolf V; Taylor P
Biochem Biophys Res Commun; 2006 Apr; 342(3):973-8. PubMed ID: 16598855
[TBL] [Abstract][Full Text] [Related]
16. The pH dependence of dealkylation in soman-inhibited cholinesterases and their mutants: further evidence for a push-pull mechanism.
Saxena A; Viragh C; Frazier DS; Kovach IM; Maxwell DM; Lockridge O; Doctor BP
Biochemistry; 1998 Oct; 37(43):15086-96. PubMed ID: 9790671
[TBL] [Abstract][Full Text] [Related]
17. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
18. Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene-di-N-substituted carbamates.
Chiou SY; Huang CF; Hwang MT; Lin G
J Biochem Mol Toxicol; 2009; 23(5):303-8. PubMed ID: 19827033
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-kinetic investigation of different sarin analogues reacting with human acetylcholinesterase and butyrylcholinesterase.
Bartling A; Worek F; Szinicz L; Thiermann H
Toxicology; 2007 Apr; 233(1-3):166-72. PubMed ID: 16904809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
